Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2019 | Medulloblastoma | Research

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis

Authors: Hye Seon Kim, Jong Bae Park, Ho-Shin Gwak, Ji-Woong Kwon, Sang-Hoon Shin, Heon Yoo

Published in: World Journal of Surgical Oncology | Issue 1/2019

Abstract

Background

Leptomeningeal carcinomatosis (LMC) is frequently associated with hydrocephalus, which quickly devastates the performance of the patient. Cerebrospinal fluid (CSF) shunt is a widely accepted treatment of choice, but the clinical outcomes in patients with LMC are not well studied. This study aimed to examine the efficacy of a CSF shunt in patients with LMC.

Methods

Seventy patients with LMC confirmed by cytology or magnetic resonance imaging (MRI) underwent ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. We retrospectively analyzed the clinical characteristics of patients, symptom improvement after the shunt, rate of complications associated with the surgery, and overall survival.

Results

Fifty-five patients had systemic cancer as a preceding disease, including lung cancer (45), breast cancer (6), and others (4). Primary brain tumors were mainly glioma (7) and medulloblastoma (5). Fifty-one patients had VP shunt, and 19 had LP shunt. After surgery, preoperative symptoms “improved” in 35 patients (50%) and were “normalized” in 24 of those patients (34%). Shunt malfunction occurred in eight patients, and infection occurred in eight patients. Seventeen patients underwent revision due to infection, shunt malfunction, or over-drainage. There were no complications associated with peritoneal seeding during a median follow-up of 3.3 months after surgery. The median overall survival was 8.7 months (95% confidence interval, 6.0–11.4) from LMC diagnosis and 4.1 months from shunt surgery.

Conclusion

VP or LP shunt is effective for patients with hydrocephalus from LMC in terms of symptom improvement and prolonging of overall survival with an acceptable rate of procedure-related complications.

Trial registration

This study was approved by the Institutional Review Board (IRB) of the National Cancer Center (retrospectively registered, NCC2018-0051).

Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13:967–77.PubMedCrossRef

Gwak HS, Lee SH, Park WS, et al. Recent advancements of treatment for leptomeningeal carcinomatosis. J Korean Neurosurg Soc. 2015;58:1–8.PubMedPubMedCentralCrossRef

Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382–5.PubMedCrossRef

Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46:19–26.PubMedCrossRef

Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.PubMedCrossRef

Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.PubMedCrossRef

Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40:2726–33.PubMedCrossRef

Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.PubMedCrossRef

Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro-Oncol. 1998;38:135–40.CrossRef

10.

Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61:633–41.PubMed

11.

Jung TY, Chung WK, Oh IJ. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg. 2014;119:80–3.PubMedCrossRef

12.

Lin N, Dunn IF, Glantz M, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115:730–6.PubMedCrossRef

13.

Lee SH, Kong DS, Seol HJ, et al. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neuro-Oncol. 2011;104:545–51.CrossRef

14.

Hoffman HJ, Hendrick EB, Humphreys RP. Metastasis via ventriculoperitoneal shunt in patients with medulloblastoma. J Neurosurg. 1976;44:562–6.PubMedCrossRef

15.

Menger RP, Connor DE Jr, Thakur JD, et al. A comparison of lumboperitoneal and ventriculoperitoneal shunting for idiopathic intracranial hypertension: an analysis of economic impact and complications using the Nationwide Inpatient Sample. Neurosurg Focus. 2014;37:E4.PubMedCrossRef

16.

Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:51–7.PubMedCrossRef

17.

Gwak HS, Joo J, Kim S, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 2013;8:599–605.PubMedCrossRef

18.

Lokich J, Levine H, Nasser I. Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Am J Clin Oncol. 1998;21:366–8.PubMedCrossRef

19.

Omuro AM, Lallana EC, Bilsky MH, et al. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology. 2005;64:1625–7.PubMedCrossRef

20.

McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg. 2004;101:627–32.PubMedCrossRef

21.

Wilson TJ, Stetler WR Jr, Al-Holou WN, et al. Comparison of the accuracy of ventricular catheter placement using freehand placement, ultrasonic guidance, and stereotactic neuronavigation. J Neurosurg. 2013;119:66–70.PubMedCrossRef

22.

Lee L, King NK, Kumar D, et al. Use of programmable versus nonprogrammable shunts in the management of hydrocephalus secondary to aneurysmal subarachnoid hemorrhage: a retrospective study with cost-benefit analysis. J Neurosurg. 2014;121:899–903.PubMedCrossRef

23.

Karabatsou K, Quigley G, Buxton N, et al. Lumboperitoneal shunts: are the complications acceptable? Acta Neurochir. 2004;146:1193–7.PubMedCrossRef

24.

Berger MS, Baumeister B, Geyer JR, et al. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg. 1991;74:872–7.PubMedCrossRef

25.

Magtibay PM, Friedman JA, Rao RD, et al. Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literature. Neuro-Oncology. 2003;5:217–20.PubMedPubMedCentralCrossRef

26.

Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology. 1996;46:1524–30.PubMedCrossRef

27.

Spetzler RF, Wilson CB, Grollmus JM. Percutaneous lumboperitoneal shunt. Technical note. J Neurosurg. 1975;43:770–3.PubMedCrossRef

28.

Aoki N. Lumboperitoneal shunt: clinical applications, complications, and comparison with ventriculoperitoneal shunt. Neurosurgery. 1990;26:998–1003 discussion 1003–1004.PubMedCrossRef

29.

Toma AK, Dherijha M, Kitchen ND, et al. Use of lumboperitoneal shunts with the Strata NSC valve: a single-center experience. J Neurosurg. 2010;113:1304–8.PubMedCrossRef

30.

Nadkarni TD, Rekate HL, Wallace D. Concurrent use of a lumboperitoneal shunt with programmable valve and ventricular access device in the treatment of pseudotumor cerebri: review of 40 cases. J Neurosurg Pediatr. 2008;2:19–24.PubMedCrossRef

31.

Zhang XH, Wang XG, Piao YZ, et al. Lumboperitoneal shunt for the treatment of leptomeningeal metastasis. Med Hypotheses. 2015;84:506–8.PubMedCrossRef

Title: Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis
Authors: Hye Seon Kim
Jong Bae Park
Ho-Shin Gwak
Ji-Woong Kwon
Sang-Hoon Shin
Heon Yoo
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Medulloblastoma
NSCLC
Medulloblastoma
Hydrocephalus
Hydrocephalus
Intracranial Hypertension
Hydrocephalus
NSCLC
Medulloblastoma
Brain Tumor
CSF Drainage
Published in: World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-019-1595-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis

Short-term outcomes of traction-assisted versus conventional endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a systematic review and meta-analysis of randomized controlled studies

Curative efficacy of low frequency electrical stimulation in preventing urinary retention after cervical cancer operation

An extremely rare primary sarcoma of the lung with peritoneal and small bowel metastases: a case report

Patient satisfaction after unilateral oncoplastic volume displacement surgery for breast cancer, evaluated with the BREAST-Q™

Clampless and sutureless laparoscopic partial nephrectomy using monopolar coagulation with or without N-butyl-2-cyanoacrylate